Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.37 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.35 |
| ▸ | CCKAR | P32238 | 3/20 | 0.35 |
| ▸ | CCKBR | P32239 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 5/20 | 0.35 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31752119 | 0.92 | ITGA4 (0.36) | ITGA4ITGB7SCN9ACCKARCCKBR | |
| SCHEMBL34466370 | 0.90 | ITGA4 (0.39) | ITGA4ITGB7SCN9ACTSSCTSK | |
| SCHEMBL31752090 | 0.90 | HDAC3 (0.34) | CTSSCTSK | |
| SCHEMBL31753209 | 0.87 | SCN9A (0.34) | ITGA4ITGB7SCN9ACCKARCCKBR | |
| SCHEMBL34466727 | 0.87 | ITGA4 (0.33) | ITGA4ITGB7SCN9ACCKARCCKBR | |
| SCHEMBL34466987 | 0.86 | HDAC3 (0.35) | — | |
| SCHEMBL34466764 | 0.85 | CTSS (0.33) | ITGA4ITGB7SCN9ACCKARCCKBR | |
| Hydrochloric Acid SCHEMBL33527082 | 0.85 | HDAC3 (0.34) | — | |
| Bromide SCHEMBL31752139 | 0.85 | HDAC3 (0.34) | — | |
| SCHEMBL31752402 | 0.85 | CTSS (0.37) | ITGA4ITGB7SCN9ACCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | ITGA4 1929/4885ITGB7 1595/4885SCN9A 504/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | ITGA4 1300/4885ITGB7 1393/4885SCN9A 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.